Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient Care
- 10 February 2014
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (5), 376-378
- https://doi.org/10.1200/jco.2013.54.2548
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- The Economics of New Drugs: Can We Afford to Make Progress in a Common Disease?Asco Educational Book, 2013
- The High Cost of Cancer Drugs and What We Can Do About ItMayo Clinic Proceedings, 2012
- Bureaucracy stifles medical research in Britain: a tale of three trialsBMC Medical Research Methodology, 2012
- Reliability of adverse symptom event reporting by cliniciansQuality of Life Research, 2011
- Global clinical trials are burdened by excessive bureaucracy, conference hearsBMJ, 2011
- Phase III Clinical Trial Development: A Process of Chutes and LaddersClinical Cancer Research, 2010
- Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group InvestigationJournal of Clinical Oncology, 2010
- The Ordinary Miracle of Cancer Clinical TrialsJournal of Clinical Oncology, 2009
- Clinical trials bureaucracy: unintended consequences of well-intentioned policyClinical Trials, 2006
- The Contract Research Organization and the Commercialization of Scientific ResearchSocial Studies of Science, 2005